An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

The purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no on

Trial Details

NCT ID
NCT07604766
Phase
PHASE3
Sponsor
Genmab
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Rina-S
  • Paclitaxel
  • Topotecan
  • Pegylated liposomal doxorubicin (PLD)
  • Gemcitabine
Locations (sample)
  • Changchun, China|43.88,125.32278
  • Changsha, China|28.19874,112.97087
  • Chengdu, China|30.66667,104.06667
  • Chongqing, China|29.56026,106.55771
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal ca…
  • Participants may be enrolled regardless of FRα expression level.
  • Participants must have received 1 to 4 prior lines of therapy. Participants must have progressed radiographically on or after their most recent lin…
  • Participants must have received prior treatment with the following therapies:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →